Skip to main content
. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473

Figure 6.

Box plots showing anti-spike IgG avidity by group and dose for two age categories (<65 and ≥65) at 1 month (panel A) and 6 months (panel B). Groups include Healthy Control, Multiple Myeloma, non-MM hematological, and Solid. Significant differences are marked with p-values in the graphs.

Anti-SARS-CoV-2 spike IgG avidity post vaccination in serum samples from cancer and healthy cohorts within different age groups (<65 years old and ≥ 65 years old). Comparison of serum anti-spike IgG avidity in healthy, multiple myeloma, non-MM hematological cancer and solid cancer cohorts within different age groups 1-month (A) and 6-months (B) post-vaccination. Anti-spike IgG avidity was presented as Geometric Mean (GM) with 95% confidence intervals (95% CI). Box plots show median (horizontal bar), the first and third quartiles. Differences assessed by non-parametric Wilcoxon rank sum test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.